Loading...
XASX
AN1
Market cap2mUSD
Jul 08, Last price  
0.01AUD
1D
0.00%
1Q
16.67%
IPO
-66.67%
Name

Anagenics Ltd

Chart & Performance

D1W1MN
XASX:AN1 chart
P/E
P/S
0.65
EPS
Div Yield, %
Shrs. gr., 5y
34.77%
Rev. gr., 5y
-8.45%
Revenues
5m
-56.07%
0000031,418141,199542,0552,196,6131,842,8043,120,3674,496,3385,647,9307,301,6867,380,8955,816,3516,945,3819,113,41410,803,1684,746,195
Net income
-1m
L-83.51%
-2,760,092-4,554,782-2,688,804-3,334,546-1,339,948-2,269,637-1,970,360-1,528,041-1,473,815-3,337,348-3,498,916-4,470,136-3,732,615-5,909,557-4,907,296-3,386,632-3,648,787-2,667,150-7,493,210-1,235,675
CFO
-2m
L-9.33%
-2,268,742-2,891,875-1,574,617-1,100,191-1,167,439-2,328,723-1,758,269-1,452,768-2,239,805-3,123,364-2,548,712-4,060,519-4,398,757-5,934,662-4,084,361-4,114,150-2,525,596-1,780,486-1,738,321-1,576,123

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Anagenics Limited engages in the health wellness and beauty business. The company develops, manufactures, and markets anti-ageing hair care products under the évolis brand name; and skin, hair, and body care products under the Uspa brand name. It also imports and distributes skin care and wellbeing products to spas, clinics, salons, retail stores, and online in Australia, New Zealand, and the Pacific Islands. The company was formerly known as Cellmid Limited and changed its name to Anagenics Limited in December 2021. Anagenics Limited was incorporated in 2004 and is based in Sydney, Australia.
IPO date
Dec 09, 2005
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT